By Sabela Ojea
AstraZeneca PLC said Friday that the Propel Phase 3 trial met its primary point, proving that its Lynparza drug significantly delayed disease progression of first-line metastatic castration-resistant prostate cancer in combination with the abiraterone drug.
The biopharmaceutical company said the results from the trial showed positive results, including a trend towards improved overall survival.
The London-listed company noted that prostate cancer is the second most common cancer.
Write to Sabela Ojea at firstname.lastname@example.org; @sabelaojeaguix
(END) Dow Jones Newswires